FI3694526T3 - Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten - Google Patents

Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten Download PDF

Info

Publication number
FI3694526T3
FI3694526T3 FIEP18865483.4T FI18865483T FI3694526T3 FI 3694526 T3 FI3694526 T3 FI 3694526T3 FI 18865483 T FI18865483 T FI 18865483T FI 3694526 T3 FI3694526 T3 FI 3694526T3
Authority
FI
Finland
Prior art keywords
cystic fibrosis
patient
agnostic
genotype
rescue
Prior art date
Application number
FIEP18865483.4T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Martin D Burke
Katrina A Muraglia
Rajeev S Chorghade
Michael J Welsh
Original Assignee
Univ Illinois
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, Univ Iowa Res Found filed Critical Univ Illinois
Application granted granted Critical
Publication of FI3694526T3 publication Critical patent/FI3694526T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP18865483.4T 2017-10-11 2018-10-11 Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten FI3694526T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762570795P 2017-10-11 2017-10-11
PCT/US2018/055435 WO2019075214A2 (en) 2017-10-11 2018-10-11 INDEPENDENT RESCUEING OF THE GENOTYPE OF CYSTIC FIBROSIS WITH BICARBONATE CHANNELS WITH SMALL MOLECULES

Publications (1)

Publication Number Publication Date
FI3694526T3 true FI3694526T3 (fi) 2025-02-06

Family

ID=66100102

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18865483.4T FI3694526T3 (fi) 2017-10-11 2018-10-11 Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten

Country Status (10)

Country Link
US (3) US12090164B2 (enExample)
EP (1) EP3694526B1 (enExample)
JP (2) JP7355335B2 (enExample)
AU (2) AU2018348214C1 (enExample)
CA (1) CA3076246A1 (enExample)
DK (1) DK3694526T3 (enExample)
ES (1) ES3009563T3 (enExample)
FI (1) FI3694526T3 (enExample)
PT (1) PT3694526T (enExample)
WO (1) WO2019075214A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3694526T (pt) 2017-10-11 2025-01-20 Univ Illinois Resgate independente do genótipo da fibrose quística com canais de bicarbonato de moléculas pequenas
IL315719A (en) 2022-03-21 2024-11-01 Univ Illinois Prosthetic assemblies of ion channels containing lipid-coated amphotericin B crystals
WO2025019806A2 (en) * 2023-07-19 2025-01-23 The Board Of Trustees Of The University Of Illinois Restoring physiology with small molecule mimics of missing proteins
EP4780466A1 (en) * 2023-09-20 2026-07-29 The Board Of Trustees Of The University Of Illinois Additive effects for molecular prosthetcs and cftr modulators in cf epithelia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
AU2003304204B2 (en) * 2002-10-29 2009-12-24 Insmed Incorporated Sustained release of antiinfectives
TWI249408B (en) 2003-12-10 2006-02-21 Ind Tech Res Inst New antifungal formulation and manufacturing method thereof
CN101014322A (zh) * 2004-06-11 2007-08-08 吉藤德拉·纳提·维玛 盐水中富含固醇的添加两性霉素的混合层状脂质体及其制备方法
US8507441B2 (en) 2009-10-22 2013-08-13 University of Pittsburgh—Of the Commonwealth Systems of Higher Education Use of endostatin peptides for the treatment of fibrosis
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
JP6796581B2 (ja) * 2014-11-04 2020-12-09 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイThe Board Of Trustees Of The University Of Illinois ミッシングタンパク質の小分子模倣体を用いた生理機能の回復
ES2983639T3 (es) 2016-04-08 2024-10-24 The Board Of Trustees Of The Univ Illinois Restauración mediada por moléculas pequeñas de la fisiología de la superficie de las vías respiratorias en epitelios pulmonares humanos de fibrosis quística
US10960018B2 (en) * 2016-04-15 2021-03-30 The Uab Research Foundation Methods and compounds for stimulating read-through of premature termination codons
PT3694526T (pt) 2017-10-11 2025-01-20 Univ Illinois Resgate independente do genótipo da fibrose quística com canais de bicarbonato de moléculas pequenas

Also Published As

Publication number Publication date
US20250000886A1 (en) 2025-01-02
WO2019075214A3 (en) 2020-04-02
ES3009563T3 (en) 2025-03-27
JP7355335B2 (ja) 2023-10-03
CA3076246A1 (en) 2019-04-18
US20250009775A1 (en) 2025-01-09
JP2020536859A (ja) 2020-12-17
AU2018348214B2 (en) 2024-08-08
EP3694526A4 (en) 2021-06-09
DK3694526T3 (da) 2025-02-03
JP2023126932A (ja) 2023-09-12
EP3694526A2 (en) 2020-08-19
US12090164B2 (en) 2024-09-17
US20200352970A1 (en) 2020-11-12
AU2024259758A1 (en) 2024-11-21
AU2018348214C1 (en) 2025-01-30
AU2018348214A1 (en) 2020-04-23
EP3694526B1 (en) 2024-12-04
WO2019075214A2 (en) 2019-04-18
PT3694526T (pt) 2025-01-20

Similar Documents

Publication Publication Date Title
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
FI3849534T3 (fi) Yhdistelmähoidot
MX379276B (es) Pirazolo [3,4-b] piridin-6-carboxamidas n-sulfoniladas y metodo de uso.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
PH12018500088A1 (en) Substituted tricyclics and method of use
WO2019036008A8 (en) Lipids for use in lipid nanoparticle formulations
MY195271A (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
MX2018004364A (es) Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso.
WO2017091767A3 (en) Drug formulations for cancer treatment
EP4599848A3 (en) Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
MY161078A (en) Topical formulation for a jak inhibitor
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MY194313A (en) Substituted chromanes and method of use
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
MX2023001445A (es) Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4.
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
SA519401614B1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
PH12018502422A1 (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
MX2021002042A (es) Inhibidores de arginasa y sus metodos de uso.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
SA519410993B1 (ar) النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE